A complete listing of PAI's
published studies follows, organized chronologically. This list is also available
organized by subject area.
To request reprints of published articles, please
click the
"Request
Articles" button to fill out our article request form, making a note of the article
numbers.
130. Weycker D, Malin J, Edelsberg J, Glass A, Gokhale M, Oster G. Cost of neutropenic complications of chemotherapy. Ann Oncol December 2007. [E-pub]
129. Vera-Llonch M, Brandenburg NA, Oster G. Cost-effectiveness of Add-on Therapy with Pregabalin in Patients with Refractory Partial Epilepsy. Epilepsia October 2007. [Epub]
128. Diaz S, Argumosa A, Horga de la Parte JF, Vera-Llonch M, Dukes E, Rejas-Gutierrez J. Análisis coste-efectividad del tratamiento de la epilepsia parcial refractaria: un modelo de simulación de pregabalina y levetiracetam. Rev Neurol October 2007.
127. Berger A, Kramarz P, Kopperud GS, Edelsberg J, Oster G. Economic impact of shifting the locus of care for neuropathic pain from specialists to general practitioners. Eur J Health Econ, January 2007. [Epub]
126. Berger A, Dukes E, Martin S, Edelsberg J, Oster G. Characteristics and healthcare costs of patients with fibromyalgia syndrome. Int J Clin Pract. September 2007.
125. Cramer JA, Brandenburg NA, Xu X, Vera-Llonch M, Oster G. The impact of seizures and adverse effects on global health ratings. Epilepsy Behav. September 2007.
124.
Weycker D, Nichols GA, O'keeffe-Rosetti M, Edelsberg J, Vincze G, Khan ZM, Oster G. Risk of chronic kidney disease in hypertensive patients with other metabolic conditions. J Hum Hypertens. August 2007. [E-pub]
123. Delea TE, Taneja C, Moynahan A, Thomas SK, Frech-Tamas F, Oster G. Valsartan versus lisinopril or extended-release metoprolol in preventing cardiovascular and renal events in patients with hypertension. Am J Health-Syst Pharm 2007, Jun 2007.
122. Weycker D, Nichols GA, O’Keeffe-Rosetti M, Edelsberg J, Khan ZM, Kaura S, Oster G. Risk-factor clustering and cardiovascular disease risk in hypertensive patients. Am J Hypertens, June 2007.
121. Weycker D, Taneja C, Edelsberg J, Erder MH, Schmitt FA, Setyawan J, Oster G. Cost-effectiveness of memantine in moderate-to-severe Alzheimer's disease patients receiving donepezil. Curr Med Res Opin, May 2007.
120. Delea TE, Gokhale M, Makin C, Hussein MA, Vanderpoel J, Sandman T, Chang J, Sung J, Pinkston P, Gause D, Jackson JM. Administrative claims analysis of utilization and costs of care in health plan members with atopic dermatitis who had prior use of a topical corticosteroid and who initiate therapy with pimecrolimus or tacrolimus. J Manag Care Pharm, May 2007.
119. Vera-Llonch M, Oster G, Ford CM, Lu J, Sonis S. Oral mucositis and outcomes of autologous hematopoietic stem-cell transplantation following high-dose melphalan conditioning for multiple myeloma. J Support Oncol, May 2007.
118. Vera-Llonch M, Oster G, Ford CM, Lu J, Sonis S. Oral mucositis and outcomes of allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies. Support Care Cancer, May 2007.
117. Weycker D, Edelsberg J, Vincze G, Kjeldsen SE, Jamerson K, Khan ZM, Oster G. Risk of diabetes in a real-world setting among patients initiating antihypertensive therapy with valsartan or amlodipine. J Hum Hypertens, May 2007.
116.
Delea TE, Sofrygin O, Thomas SK, Baladi JF, Phatak PD, Coates TD. Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients : US healthcare system perspective.
Pharmacoeconomics, April 2007.
115. Weycker D, Macarios D, Edelsberg J, Oster G. Compliance with osteoporosis drug therapy and risk of fracture. Osteoporos Int, March 2007.
114. Berger A, Dukes E, Edelsberg, Stacey B, Oster G. Use of tricyclic antidepressants in older patients with diabetic peripheral neuropathy. Clin J Pain, March/April 2007.
113. El Ouagari K, Karnon J, Delea T, Talbot W, Brandman J. Cost-effectiveness of letrozole in the extended adjuvant treatment of women with early breast cancer. Breast Cancer Res Treat, Jan 2007.
112. Tarride J-E, Gordon A, Vera-Llonch M, Dukes E, Rousseau C. Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: A Canadian perspective. Clin Ther, November 2006.
111. Edelsberg J, Hagiwara M, Taneja C, Oster G. Risk of venous thromboembolism among hospitalized medically ill patients. Am J Health-Syst Pharm, October 2006.
110. Raghu G, Weycker D, Eelsberg J, Bradford WZ, Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med, October 2006.
109. Berger A, Dukes EM, Edelsberg J, Stacey BR, Oster G. Use of tricyclic antidepressants in older patients with painful neuropathies. Eur J Clin Pharmacol, September 2006.
108. Delea T, McKiernan J, Brandman J, Edelsberg J, Sung J, Raut M, Oster G. Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice. J Support Oncol, July/August 2006.
107. Delea TE, McKiernan J, Brandman J, Edelsberg J, Sung J, Raut M, Oster G. Impact of skeletal complications on total medical care costs among patients with bone metastases of lung cancer. J Thorac Oncol, July 2006.
106. Delea TE, Karnon J, Smith RE, Johnston SRD, Brandman J, Sung JCY, Goss PE. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer. Am J Manag Care, July 2006.
105. Weycker D, Macarios D, Edelsberg J, Oster G. Compliance with drug therapy for post menopausal osteoporosis. Osteoporos Int, July 2006.
104. Karnon J, Delea T, Johnston SRD, et al. Cost effectiveness of extended adjuvant letrozole in postmenopausal women after adjuvant tamoxifen therapy. Pharmacoeconomics, March 2006.
103. Weycker D, Hackett J, Edelsberg JS, Oster G, Glass AG. Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization? Ann Pharmacother, March 2006.
102. Vera-Llonch M, Oster G, Hagiwara M, Sonis S. Oral mucositis in patients undergoing radiation treatment for head and neck carcinoma. Cancer, February 2006.
101. Vera-Llonch M, Hagiwara M, Oster G. Clinical and economic consequences of bleeding following major orthopedic surgery. Throm Res, May 2005 [Epub].
100. Berger A, Edelsberg J, Li TT, Maclean JR, Oster G. Dose intensification with infliximab in patients with rheumatoid arthritis. Ann Pharmacother, December 2005.
99. Delea T, Jacobson T, Serruys P, Edelsberg J, Oster G. Cost-effectiveness of fluvastatin following successful first percutaneous coronary intervention. Ann Pharmacother, April 2005.
98. Berger A, Dukes E, Mercadante S, Oster G. Use of antiepileptics and tricyclic antidepressants in cancer patients with neuropathic pain. Eur J Cancer Care, October 2005.
97. Weycker D, Edelsberg J, Oster G, Tino G. Prevalence and economic burden of bronchiectasis. Clin Pulm Med, July 2005.
96. Martines FJ, Safrin S, Weycker D, et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med, June 2005.
95. Vera Llonch M, Dukes E, Delea TE, Wang ST, Oster G. Treatment of peripheral neuropathic pain: A simulation model. European J Pain, June 2005.
94. Oster G, Harding G, Dukes E, Edelsberg J, Cleary PD. Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: Results from a population-based survey. J Pain, June 2005.
93. Weycker D, Yu EB, Wooley JM, Oster G. Retrospective study of the costs of care during the first year of therapy with etanercept or infliximab among patients aged ›65 years with rheumatoid arthritis. Clin Ther, May 2005.
92. Delea TE, Stanford R, Hagiwara M, Edelsberg JS, Oster G. Death and hospitalization in heart failure patients receiving carvedilol vs. metoprolol tartrate. Intl J Cardiology, March 2005.
91. Weycker D, Edelsberg J, Halloran ME, et al. Population-wide benefits of routine vaccination of children against influenza. Vaccine, January, 2005.
90. Delea T, Langer C, McKiernan J, Liss M, Edelsberg J, Brandman J, Sung J, Raut M, Oster G. The cost of treatment of skeletal-related events inpatients with bone metasteses from lung cancer. Oncology, November, 2004.
89. Elmer PJ, Brown JB, Nichols GA, Oster G. Effects of weight gain on medical care costs. Int J Obes Relat Metab Disord, November, 2004.
88. Oster G, Berger A, Dukes E, Edelsberg J, McCarberg B. Use of potentially inappropriate pain-related medications in older adults with painful neuropathic disorders. Am J Geriatr Pharmacother, September 2004.
87. Vera-Llonch M, Delea TE, Richardson E, et al. Outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders: A Markov Model. Value Health, September 2004.
86. Sullivan SD, Davidson BL, Kahn SR, et al. A cost-effectiveness analysis of fondaparinux sodium compared with enoxaparin sodium as prophylaxis against venous thromboemboslism: Use in patients undergoing major orthopaedic surgery. Pharmacoeconomics, September 2004.
85. Mahmoud RA, Englehart LM, Janagap CC, Oster G, Ollendorf D. Risperdone versus conventional antipsychotics for schizophrenia and schizoaffective disorder: Symptoms, quality of life and resource use under customary clinical care. Clin Drug Invest, May 2004.
84. Berger
A, Dukes E, Oster G. Clinical characteristics and economic
costs of patients with painful neuropathic disorders. Journal of Pain, May 2004.
83. Berger A, Smith M,
Lidsky L, Seifeldin R, Oster G. Opioid use and health
care charges at the end of life in patients with metastatic
cancer. Managed Care Interface, April 2004.
82. Manco-Johnson M,
Morrissey-Harding G, Edelman-Lewis B, Oster G, Larson P.
Development and validation of a measure of disease-specific
quality of life in young children with haemophilia. Haemophilia,
March 2004.
81. Berger A, Hoffman
DL, Goodman S, Delea TE, Seifeldin R, Oster G. Therapy
switching in patients receiving long-acting opioids. Annals
of Pharmacotherapy, March 2004.
80. Oster
G, Ollendorf DA, Vera-Llonch M, Hagiwara M, Berger A, Edelsberg
J. Economic consequences of venous thromboembolism following
major orthopedic surgery. Annals of Pharmacotherapy, March
2004.
79. Berger A, Dukes E,
McCarberg B, Liss M, Oster G. Change in opioid use after
the initiation of gabapentin therapy in patients with postherpetic
neuralgia. Clinical Therapeutics, November 2003.
78. Weycker D, Akhras
KS, Edelsberg J, Angus DC, Oster G. Long-term mortality
and medical care charges in patients with severe sepsis. Critical Care Medicine, September 2003.
77. Delea
TE, Edelsberg JS, Hagiwara M, Oster G, Phillips LS. Use of
thiazolidinesdiones and risk of heart failure in people with
Type 2 diabetes. Diabetes Care, November, 2003.
76. Berger A. Dukes E,
Smith M, Hagiwara M, Seifeldin R, Oster G. Use of oral
and transdermal opioids among patients with metastatic cancer
during the last year of life. Journal of Pain & Symptom
Management, August 2003.
75. Rello J, Ollendorf
DA, Oster G, Vera-Llonch M, et al. Epidemiology and outcomes
of ventilator-associated pneumonia in a large US database. Chest,
December 2002.
74. Ollendorf DA, Vera-Llonch
M, Oster G. Cost of venous thromboembolism following major orthopedic
surgery in hospitalized patients. American Journal of
Health-System Pharmarcy, September 2002.
73. Bellm LA, Cunningham
G, Durnell L, et al. Defining clinically meaningful outcomes
in the evaluation of new treatments for oral mucositis: Oral
Mucositis Patient Provider Advisory Board. Cancer Investigation,
May/June 2002.
72. Ollendorf DA, Fendrick
AM, Massey K, et al. Is sepsis accurately coded on hospital
bills? Value in Health, March/April 2002.
71. Delea TE, Vera-Llonch M, Edelsberg J, et al. The incidence
and cost of hospitalization for 5-FU toxicity among Medicare
beneficiaries with metastatic colon cancer. Value in Health,
January/February 2002.
70. Brown JB, Delea TE, Nichols GA, et al. Use of oral antithrombotic
agents among health maintenance organization members with atherosclerotic
cardiovascular disease. Archives of Internal Medicine, January
2002.
69. Edelsberg J, Ollendorf D, Oster G. Venous thromboembolism
following major orthopedic surgery: Review of epidemiology and
economics. American Journal of Health Systems Pharmacy. November, 2001.
68. Vera-Llonch MV, Menzin
J, Richner R, Oster G. Cost-Effectiveness Results from the US
Carvedilol Heart Failure Trials Program. The Annals of Pharmacotherapy,
July 2001.
67. Fowler MB, Vera-Llonch M, Oster G, Bristow MR, Cohn JN,
Colucci WS, et al. Influence of carvedilol on hospitalizations
in heart failure: Incidence, resource utilization and costs.
Journal of American College of Cardiology, May 2001.
66. Cheville A, Chen A, Oster G, McGarry L, Narcessian E. A
randomized trial of controlled-release oxycodone during inpatient
rehabilitation following unilateral total knee arthroplasty.
Journal of Bone and Joint Surgery, May 2001.
65. Sonis ST, Oster G, Fuchs H, Bellm L, Bradford WZ, Edelsberg
J, et al. Oral mucositis and the clinical and economic outcomes
of hematopoietic stem-cell transplantation. Journal of Clinical
Oncology, April 2001.
64. Thompson D, Brown JB, Nichols GA, Elmer PJ, Oster G. Body
mass index and future healthcare costs: A retrospective cohort
study. Obesity Research, March 2001.
63. Oster G, Edelsberg J, Pozniak A, Thompson D. Resource utilization
and costs of treatment with doxazosin versus tamsulosin in men
with benign prostatic hyperplasia. Journal of Outcomes Research,
December 2000.
62. Weycker D, Richardson E, Oster G. Childhood vaccination
against pneumococcal otitis media and pneumonia: An analysis
of benefits and costs. American Journal of Managed Care, July
2000.
61. Oster G, Edelsberg J, O'Sullivan AK, Thompson D. The clinical
and economic burden of obesity in a managed care setting. American
Journal of Managed Care, May 2000.
60. Ollendorf D, McGarry L, Watrous M, Oster G. Use of rhDnase
therapy and costs of respiratory-related care in patients with
cystic fibrosis. Annals of Pharmacotherapy, March 2000.
59. Thompson D, Edelsberg J, Colditz GA, Bird AP, Oster G. The
lifetime health and economic consequences of obesity. Archives
of Internal Medicine, October 1999.
58. Oster G, Thompson D, Edelsberg J, Bird AP, Colditz GA. The
lifetime health and economic benefits of weight loss among persons
who are obese. American Journal of Public Health, October 1999.
57. Thompson D, Oster G, McGarry LJ, Klein JO. Management of
otitis media among children in a large health insurance plan.
The Pediatric Infectious Disease Journal, March 1999.
56. Delea T, Vera-Llonch M, Richner R, Fowler MB, Oster G. The
cost-effectiveness of carvedilol for heart failure. The American
Journal of Cardiology, March 15, 1998.
55. Thompson D, Edelsberg J, Kinsey K, Oster G. Estimated economic
costs of obesity to U.S. business. American Journal of Health
Promotion, Nov/Dec 1998.
54. Mahmoud R, Engelhart L, Ollendorf D, Oster G. The Risperidone
Outcomes Study of Effectiveness (ROSE): A model for evaluating
treatment strategies in typical psychiatric practice. Journal
of Clinical Psychiatry, October 1998.
53. Oster G. The economics of hypercholesterolemia and lipid-lowering
therapy: A brief historical tour. Value in Health, Fall 1998.
52. Delea T. Use of surrogate measures in cost-effectiveness
analyses of lipid-lowering therapies. Value in Health, Fall
1998.
51. Ollendorf DA, Kotsanos JG, Wishner WJ, Friedman M, Cooper
T, Bittoni M, Oster G. Potential economic benefits of lower-extremity
amputation prevention strategies in diabetes. Diabetes Care,
August 1998.
50. Thompson D, Hylan TR, McMullen W, Romeis ME, Buesching D,
Oster G. Predictors of a medical-offset effect among patients
receiving antidepressant therapy. American Journal of Psychiatry,
June 1998.
49. Thompson D, Buesching D, Gregor KJ, Oster G. Patterns of
antidepressant use and their relation to costs of care. American
Journal of Managed Care, October 1996.
48. Thompson D, Oster G. Use of terfenadine and contraindicated
drugs. Journal of the American Medical Association, May 1, 1996.
47. Oster G, Delea TE, Huse DM, et al. The benefits and risks
of over-the-counter availability of nicotine polacrilex ('nicotine
gum'). Medical Care, May 1996.
46. Oster G, Borok GM, Menzin, J, et al. The Cholesterol-Reduction
Intervention Study: A randomized trial to assess effectiveness
and costs in clinical practice. Archives of Internal Medicine,
April 1996.
45. Oster G, Thompson D. Estimated effects of reducing dietary
saturated fat intake on the incidence and costs of coronary
heart disease in the United States. Journal of the American
Dietetic Association, February 1996.
44. Menzin J, Oster G, Davies L, Drummond M, et al. A multinational
economic evaluation of rhDNase in the treatment of cystic fibrosis.
The International Journal of Technology Assessment in Health
Care, Winter 1996.
43. Cleary P, Harding GM, Oster G, Health-related quality of
life in patients with advanced prostate cancer: A multi-national
perspective. Quality of Life Research, June 1995.
42. Oster G, Huse DM, Lacey M, et al. Effects of recombinant
human DNase therapy on healthcare use and costs in patients
with cystic fibrosis. The Annals of Pharmacotherapy, May 1995.
41. Menzin J, Colditz G, Regan M, et al., Cost-effectiveness
of enoxaparin versus low-dose warfarin in the prevention of
venous thromboembolism following total hip replacement surgery.
Archives of Internal Medicine, April 1995.
40. Drummond M, Menzin J, Oster G. Methodologic issues in economic
assessments of new therapies: The case of colony-stimulating
factors. PharmacoEconomics, 1994 (Supplement 2).
39. Oster G, Menzin J, Richard D, Cour-Chabernaud V. Overview
of the lenograstim pharmacoeconomics program. PharmacoEconomics,
1994 (Supplement 2).
38. Oster G, Menzin J, Richard D, Cour-Chabernaud V. Pharmacoeconomic
evaluation of lenograstim: Conclusions and future directions.
PharmacoEconomics, 1994 (Supplement 2).
37. Cleary P, Morrissey G, Yver A, Oster G. The effects of rG-CSF
on health-related quality of life in children with congenital
agranulocytosis. Quality of Life Research, November 1994.
36. Oster G, Borok G, Menzin J, et al. A randomized trial to
assess effectiveness and cost in clinical practice: Rationale
and design of the Cholesterol-Reduction Intervention Study (CRIS).
Controlled Clinical Trials, February 1995.
35. Thompson D, Schultz N, Oster G. Comparative antifungal therapy:
Outcomes and costs. P & T, August 1994.
34. Huse DM, Meissner HC, Lacey MJ, Oster G. Childhood vaccination
against chickenpox: An analysis of benefits and costs. The Journal
of Pediatrics, June 1994.
33. Oster G, Huse DM, Lacey M, Epstein AM. The cost-effectiveness
of ticlopidine in preventing stroke in high-risk patients. Stroke,
June 1994.
32. Oster G, Borok G, Menzin J, et al. The Cholesterol-Reduction
Intervention Study (CRIS) (abstract). Clinical Research, April
1994.
31. Menzin J, Richner R, Huse DM, Colditz GA, Oster G. Prevention
of deep-vein thrombosis following total-hip replacement surgery
with enoxaparin versus unfractionated heparin: A pharmacoeconomic
evaluation. The Annals of Pharmacotherapy, February 1994.
30. Weis K, Epstein RS, Huse DM, Deverka, P, Oster G. The costs
of prostatectomy for benign prostatic hyperplasia. The Prostate,
June 1993.
29. Thompson D, Huse DM, Oster G. Outcomes of cefazolin versus
ceftriaxone therapy in treating lower respiratory tract infections
in adults. The Annals of Pharmacotherapy, December 1992.
28. Glick H, Heyse JF, Thompson D, et al. A model for evaluating
the cost-effectiveness of cholesterol-lowering treatment. International
Journal of Technology Assessment in Health Care, Fall 1992.
27. Menzin J, Huse DM, Richner R, Oster G. Economic evaluation
of oral ofloxacin versus standard parenteral therapy in the
treatment of pneumonia. PharmacoEconomics, August 1992.
26. Thompson D, Oster G. Cost-effectiveness of drug therapy
for hypercholesterolemia. PharmacoEconomics, July 1992.
25. Cleary PD, Epstein AM, Oster G, et al. Health-related quality
of life among patients undergoing percutaneous transluminal
coronary angioplasty. Medical Care, September 1991.
24. Huse DM, Menzin J, Thompson D, Oster G. Inpatient outcomes
research: Injectable cephalosporin therapy for pediatric pneumonia.
P&T, April 1991.
23. Oster G, Huse DM, Adams SF, Imbimbo J, Russell MW. Benzodiazepine
tranquilizers and the risk of accidental injury. American Journal
of Public Health, December 1990.
22. Huse DM, Oster G. Cost-effectiveness of drug therapy: Application
of the concept: Part III. P&T, September 1990.
21. Oster G, Huse DM, Delea TE, Colditz GA, Richter JM. The
risks and benefits of an Rx-to-OTC switch: The case of over-the-counter
H2-blockers. Medical Care, September 1990.
20. Menzin J, Oster G. Cost-effectiveness of drug therapy: Application
of the concept, Part II. P&T, July 1990.
19. Thompson D, Oster G. Cost-effectiveness of drug therapy:
Application of the concept, Part I. P&T, May 1990.
18. Huse DM, Oster G, Killen AR, Lacey MJ, Colditz GA. The economic
costs of noninsulin-dependent diabetes mellitus. Journal of
the American Medical Association, November 17, 1989.
17. Richter JM, Colditz GA, Huse DM, Delea TE, Oster G. Cimetidine
and adverse reactions: A meta-analysis of randomized clinical
trials of acute therapy. American Journal of Medicine, September
1989.
16. Killen AR, Oster G, Colditz GA. An assessment of the role
of 1-123-N-isopropyl- P-iodoamphetamine in the diagnosis of
stroke and Alzheimer's disease. Nuclear Medicine Communications,
February 1989.
15. Cummings SR, Rubin SM, Oster G. The cost-effectiveness of
counseling smokers to quit. Journal of the American Medical
Association, January 6, 1989.
14. Oster G, Delea TE, Colditz GA. Maternal smoking during pregnancy
and expenditures of neonatal health care. American Journal of
Preventive Medicine, 1988.
13. Savage DD, McGee DL, Oster G. Reduction of hypertension-associated
heart disease and stroke among black Americans: Past experience
and new perspectives on targeting resources. Milbank Memorial
Fund Quarterly, 1987.
12. Oster G, Delea TE. Comment: Cost-effectiveness methodology.
Drug Intelligence and Clinical Pharmacy, May 1988.
11. Oster G. Economic aspects of clinical decision making: Applications
in patient care. American Journal of Hospital Pharmacy, March
1988.
10. Oster G, Russell MW, Adams SF, Imbimbo J, Huse DM. Accident-
and injury-related health care utilization among benzodiazepine
users and nonusers. Journal of Clinical Psychiatry, December
1987.
9. Oster G, Epstein AM. The cost-effectiveness of antihyperlipemic
therapy in the prevention of coronary heart disease: The case
of cholestyramine. Journal of the American Medical Association,
November 6, 1987.
8. Oster G, Huse DM, Delea TE, Savage DD, Colditz GA. Cost-effectiveness
of labetalol and propranolol in the treatment of hypertension
among blacks. Journal of the National Medical Association, October
1987.
7. Oster G, Tuden RL, Colditz GA. Prevention of venous thromboembolism
after general surgery: A cost-effectiveness analysis of alternative
approaches to prophylaxis. American Journal of Medicine, May
1987.
6. Oster G, Epstein AM. Cholesterol reduction and health policy:
Taking clinical science to patient care. Annals of Internal
Medicine, April 1987.
5. Oster G, Tuden RL, Colditz GA. A cost-effectiveness analysis
of prophylaxis against deep-vein-thrombosis in major orthopedic
surgery. Journal of the American Medical Association, January
9, 1987.
4. Oster G, Delea TE, Huse DM, Colditz GA. The cost-effectiveness
of nicotine gum as an adjunct to physician's advice against
cigarette smoking. Journal of the American Medical Association,
September 12, 1986.
3. Oster G, Tuden RL, Colditz GA. Rates of venous thromboembolism
in general surgical patients: Combined results from randomized
clinical trials. The Lancet, July 19, 1986.
2. Oster G, Epstein AM. Primary prevention and coronary heart
disease: The economic benefits of lowering serum cholesterol.
American Journal of Public Health, June 1986.
1. Oster G, Colditz GA, Kelly NL. The economic costs of smoking
and benefits of quitting for individual smokers. Preventive
Medicine, July 1984.
|
